Advertisement
U.S. markets closed

Atara Biotherapeutics, Inc. (ATRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7080-0.0048 (-0.67%)
At close: 04:00PM EDT
0.7400 +0.03 (+4.52%)
After hours: 07:35PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close0.7128
Open0.7124
Bid0.6858 x 300
Ask0.7322 x 800
Day's Range0.7000 - 0.7400
52 Week Range0.1990 - 3.0800
Volume1,188,873
Avg. Volume2,844,800
Market Cap84.506M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-2.6100
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Atara Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • Business Wire

    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    THOUSAND OAKS, Calif., April 05, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Bi

  • Zacks

    Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

    Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

    THOUSAND OAKS, Calif., March 28, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024.